Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Fidia Farmaceutici Spa
Deal Size : Undisclosed
Deal Type : Divestment
Details : The agreement covers the registrations, trademarks, and related commercial rights of seven products, including four corticosteroids and one non-steroidal anti-inflammatory drug, across Europe and Emerging Markets.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 23, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Fidia Farmaceutici Spa
Deal Size : Undisclosed
Deal Type : Divestment
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Inside Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
OSE Immunotherapeutics forms Strategic Collaboration on Novel mRNA Tech
Details : OSE will develop novel RNA therapeutics and delivery methods to fine-tune immune responses in inflammatory disorders and autoimmune diseases, leveraging the advantages of RNA-based therapy.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
May 21, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Inside Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Arsenic Trioxide
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Phebra
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Biosenic Provides Update Regarding Current License Agreement With Phebra
Details : Under the license agreement, Medsenic agreed to commence a clinical study using Phebra's oral formulation OATO (arsenic trioxide) for the treatment of Graft Versus Host Disease, Systemic Sclerosis, Systemic Lupus Erythematosus and infectious diseases.
Product Name : Arscimed
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
May 29, 2023
Lead Product(s) : Arsenic Trioxide
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Phebra
Deal Size : Undisclosed
Deal Type : Licensing Agreement